Business
Exercise of options and PDMR dealing
Exercise of options and PDMR dealing.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n Arecor Therapeutics plc\n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n \n Exercise of rollover options, PDMR dealing and Total Voting Rights\n \n \n \n \n \n \n \n \n Cambridge, UK, \n 8 November\n 2022:\n \n Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives\n ,\n \n announces that it has issued and allotted 131,433 new Ordinary Shares of 1 pence each in the share capital of the Company following an exercise of options on 7 November 2022 at an exercise price of 1 pence per Ordinary Share. The options exercised were part of the rollover of share options previously granted under the historic\n Arecor Limited EMI Share Option Plan 2018\n (\"Option Rollover\"). Details of the Option Rollover are set out in the Company's Admission Document.\n \n \n \n \n \n Included in the exercise of options were options over 109,958 ordinary shares held by Directors/PDMRs of the Company as detailed in the table below:\n \n \n \n \n \n \n \n \n \n \n Director/ PDMR\n \n \n \n \n \n \n Position\n \n \n \n \n \n \n Existing interest in Ordinary Shares\n \n \n \n \n \n \n Number of Options over Ordinary Shares exercised\n \n \n \n \n \n \n Resultant interest in Ordinary Shares\n \n \n \n \n \n \n Rollover options remaining after exercise\n \n \n \n \n \n \n \n David Gerring\n \n \n \n \n VP, Development\n \n \n \n \n 151,292\n \n \n \n \n 3,334\n \n \n \n \n 154,626\n \n \n \n \n 0\n \n \n \n \n \n \n Sarah Howell\n \n \n \n \n Chief Executive Officer\n \n \n \n \n 847,072\n \n \n \n \n 20,666\n \n \n \n \n 867,738\n \n \n \n \n 0\n \n \n \n \n \n \n Jan Jezek\n \n \n \n \n Chief Scientific Officer\n \n \n \n \n 404,474\n \n \n \n \n 3,334\n \n \n \n \n 407,808\n \n \n \n \n 0\n \n \n \n \n \n \n Fiona Lawrence\n \n \n \n \n VP, Clinical & Regulatory Affairs\n \n \n \n \n 70,334\n \n \n \n \n 1,666\n \n \n \n \n 72,000\n \n \n \n \n 0\n \n \n \n \n \n \n Susan Lowther\n \n \n \n \n Chief Financial Officer\n \n \n \n \n 139,849\n \n \n \n \n 62,000\n \n \n \n \n 201,849\n \n \n \n \n 0\n \n \n \n \n \n \n James MacDonald-Clink\n \n \n \n \n VP, Business Development\n \n \n \n \n 25,000\n \n \n \n \n 18,958\n \n \n \n \n 43,958\n \n \n \n \n 16,042\n \n \n \n \n \n \n \n \n \n \n \n \n \n Admissio...